Merano

Researchers are evaluating the effects and safety of two different doses of rilzabrutinib in adults with Graves disease, including those with and without Graves orbitopathy. This Phase 2, randomized, parallel-group study aims to measure how these doses impact thyroid hormone levels, particularly FT4, over a treatment period. Participants will receive one of two oral doses of rilzabrutinib during the treatment phase lasting up to 16 weeks. The study includes a screening period of up to 4 weeks before treatment begins and a 4-week follow-up after treatment ends. Participants are randomly assigned to either of the two rilzabrutinib dose groups for evaluation. During the study, participants will attend up to 13 visits where their thyroid hormone levels FT4 and FT3 will be measured, along with monitoring for any adverse events. The primary outcome is the percent change in FT4 levels at Week 16, with secondary outcomes including changes in FT3 levels and safety assessments up to Week 20. The total duration for each participant is about 24 weeks, including screening, treatment, and follow-up periods.

This research aims to find simple external body landmarks that can reliably predict the correct depth for inserting an esophageal probe. Accurate placement in the lower third of the esophagus is important for precise core temperature monitoring. The study focuses on adult ICU patients who need transesophageal echocardiography TEE as part of their clinical care. The Institute of Mountain Emergency Medicine is sponsoring this observational study. Participants will undergo clinically needed transesophageal echocardiography, which will be used as the gold standard to confirm correct esophageal probe placement. During the procedure, researchers will measure several external anatomical points to predict insertion depth and compare these predictions with TEE-confirmed probe positions. The study will analyze how well the landmark-based method agrees with the TEE standard. Throughout the study, adult ICU patients will be evaluated during their routine TEE procedure. Researchers will collect anatomical measurements and confirm probe positions to assess accuracy. The main outcome is the agreement between the predicted insertion depth and the actual depth confirmed by TEE. The study will monitor results during the procedure period, supporting better methods for esophageal temperature monitoring in critical care.

Acute respiratory distress syndrome ARDS is a serious lung condition causing inflammation and fluid buildup, leading to severe breathing problems and high mortality in intensive care units worldwide. Despite many clinical trials, no specific drug has yet proven effective in treating ARDS. The study aims to evaluate the anti-fibrotic medication Pirfenidone, previously used for idiopathic pulmonary fibrosis, to see if it can prevent lung fibrosis and improve outcomes in ARDS patients. Participants will be randomly assigned to receive either Pirfenidone or a placebo. Pirfenidone dosing starts at 801 mg per day for the first week, increases to 1602 mg per day for the second week, and then to 2403 mg per day until ICU discharge. The medication or placebo is given through a nasogastric tube in three divided doses daily. This is a phase 3 randomized controlled trial conducted across multiple centers. Throughout the study, researchers will monitor the number of days participants are free from ventilators within 28 days, length of ICU stay, lung imaging changes, mortality rates, lung function tests, heart function, and quality of life up to one year. Samples from the lungs will also be collected to study inflammation. Safety and any adverse effects will be closely tracked. The study will continue until December 2026.